23 completed. 23 Phase 2, 7 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 23 | Completed 23 |
| Phase 3 | 7 | Completed 7 |
| Phase 1 | 2 | Completed 2 |
Follow COVID: new trials by email Literature Review of COVID trials Research Report on COVID
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) LSALT peptide, Placebo - COVID, Severe Acute Respiratory Syndrome | Phase 2 | Completed | Arch Biopartners Inc. | 61 | 2020-10-14 | 2025-07-09 |
| Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease N-acetylcysteine - COVID, Sars-CoV2 | Phase 2 | Completed | Cambridge Health Alliance | 165 | 2020-09-23 | 2021-05-28 |
| Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease NP-120 (Ifenprodil) - COVID | Phase 2 / Phase 3 | Completed | Algernon Pharmaceuticals | 168 | 2020-08-05 | 2021-12-03 |
| Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation mavrilimumab, Placebo - COVID | Phase 2 / Phase 3 | Completed | Kiniksa Pharmaceuticals International, plc | 814 | 2020-07-28 | 2025-01-22 |
| Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS Ruxolitinib administration - ARDS, Human, COVID | Phase 2 | Completed | Philipps University Marburg | 15 | 2020-07-01 | 2021-08-24 |
| A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection Hydroxychloroquine, Vitamin C, Vitamin D - COVID-19, Coronavirus Infection | Phase 2 | Completed | ProgenaBiome | 254 | 2020-06-22 | 2026-11-04 |
| Remdesivir Efficacy in Coronavirus Disease Remdesivir, Standard of care treatment - COVID | Phase 2 / Phase 3 | Completed | Tanta University | 200 | 2020-06-16 | 2021-08-02 |
| Using GM-CSF as a Host Directed Therapeutic Against COVID-19 Sargramostim, Normal Saline 0.9% - COVID, Sars-CoV2 | Phase 2 | Completed | Singapore General Hospital | 2 | 2020-06-02 | 2022-05-10 |
| Ivermectin as a Novel Therapy in COVID-19 Treatment Ivermectin - COVID | Phase 2 / Phase 3 | Completed | Tanta University | 164 | 2020-06-01 | 2021-08-02 |
| Prophylactic Ivermectin in COVID-19 Contacts Ivermectin Tablets - COVID | Phase 2 / Phase 3 | Completed | Zagazig University | 340 | 2020-05-31 | 2020-08-27 |
| Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19 Dipyridamole 100 Milligram(mg), Placebo oral tablet - COVID, Corona Virus Infection | Phase 2 | Completed | University of Michigan | 99 | 2020-05-31 | 2022-03-24 |
| A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 APL-9, Vehicle Control - COVID, Covid-19 | Phase 1 / Phase 2 | Completed | Apellis Pharmaceuticals, Inc. | 72 | 2020-05-28 | 2022-03-23 |
| Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells Allogenic pooled olfactory mucosa-derived mesenchymal stem cells, Standard treatment according to the Clinical protocols - COVID, Covid-19 | Phase 1 / Phase 2 | Completed | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | 32 | 2020-05-11 | 2021-08-23 |
| Convalescent Plasma for Patients With COVID-19 Convalescent plasma - Coronavirus Infection, Coronavirus | Phase 2 | Completed | Henry Ford Health System | 30 | 2020-05-04 | 2022-05-02 |
| Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE ) avdoralimab, Placebo - COVID | Phase 2 | Completed | Assistance Publique Hopitaux De Marseille | 208 | 2020-04-27 | 2021-05-27 |
| A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic Azithromycin 500 milligram (mg) oral Tablet, Placebo - COVID | Phase 2 | Completed | Prof. Dr. Matthias Preusser | 74 | 2020-04-27 | 2022-04-07 |
| Nebulised Rt-PA for ARDS Due to COVID-19 Nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 1, Nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 IMV, Nebulised recombinant tissue-Plasminogen Activator (rt-PA) - Cohort 2 NIV - COVID | Phase 2 | Completed | University College, London | 35 | 2020-04-22 | 2025-08-11 |
| Efficacy of Faviprevir in COVID-19 Treatment Favipiravir, Chloroquine - COVID | Phase 2 / Phase 3 | Completed | Tanta University | 92 | 2020-04-20 | 2021-11-01 |
| Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients Convalescent Plasma Transfusion, Supportive Care, Random Donor Plasma - COVID | Phase 2 | Completed | Institute of Liver and Biliary Sciences, India | 29 | 2020-04-20 | 2020-06-12 |
| Convalescent Plasma in the Treatment of COVID 19 Convalescent Plasma - Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), COVID | Phase 2 | Completed | Trinity Health Of New England | 48 | 2020-04-10 | 2020-09-24 |
Showing 20 of 23. Sign in to see all of them.
COVID-19 (11) · Coronavirus Infections (6) · Respiratory Distress Syndrome (4) · Pneumonia (3) · Severe Acute Respiratory Syndrome (3) · Acute Kidney Injury (1) · Acute Lung Injury (1) · Lung Diseases, Interstitial (1) · Pneumonia, Viral (1)
Coronaviridae Infections (13) · Infections (13) · Nidovirales Infections (13) · RNA Virus Infections (13) · Respiratory Tract Diseases (13) · Respiratory Tract Infections (13) · Virus Diseases (13) · Lung Diseases (12) · Pneumonia, Viral (10) · Pneumonia (8) · Coronavirus Infections (7) · Respiration Disorders (4) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Kidney Diseases (1)
Hydroxychloroquine (2) · Ivermectin (2) · Acetylcysteine (1) · Ascorbic Acid (1) · BID protein, human (1) · Chloroquine (1) · Colony-Stimulating Factors (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Interferon beta-1b (1) · Lopinavir (1) · Palliative Care (1) · Ritonavir (1) · Saline Solution (1) · Tablets (1) · Vitamin D (1)
Tanta University (3) · Algernon Pharmaceuticals (1) · Apellis Pharmaceuticals, Inc. (1) · Arch Biopartners Inc. (1) · Assistance Publique Hopitaux De Marseille (1) · Cambridge Health Alliance (1) · Fabrizio Cantini (1) · Henry Ford Health System (1) · Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus (1) · Institute of Liver and Biliary Sciences, India (1) · Kiniksa Pharmaceuticals International, plc (1) · Philipps University Marburg (1) · Prof. Dr. Matthias Preusser (1) · ProgenaBiome (1) · Singapore General Hospital (1)
United States (10) · Egypt (4) · Brazil (2) · Australia (1) · Austria (1) · Belarus (1) · Canada (1) · Chile (1) · France (1) · Germany (1) · Hong Kong (1) · India (1) · Italy (1) · Peru (1) · Philippines (1)
Andreas Neubauer, Prof Dr. (1) · Andrei Y Hancharou, Dr. (1) · Eduard A Dotsenko, Dr., prof. (1) · Emilie Garrido-Pradalie (1) · Geneva Tatem, MD (1) · Ivan FN Hung, MD FRCP (1) · Jason Knight, MD, PhD (1) · Jenny Low, MBBS (1) · Latha Dulipsingh, MD (1) · Natalia G Antonevich, Dr. (1) · Pratima Chowdary (1) · Sabine Hazan, MD (1) · Sherief Abd-Elsalam, ass. prof. (1) · Westyn Branch-Elliman, MD (1)
PMID 34013969, PMID 36734509, PMID 37162745, PMID 32883593, PMID 32951151, PMID 33044747, PMID 33492523, PMID 34385593, PMID 34473343, PMID 35213547, PMID 36218354, PMID 36695483, PMID 36782325, PMID 37489818, PMID 38490660